| GALAPAGOS N.V. | 63.58 / -0.58% |
News
- Galapagos increases share capital through subscription right exercises
06/07/2021 / 22:01 - GlobeNewswire - SELECTION study on filgotinib in ulcerative colitis published in The Lancet
06/04/2021 / 07:01 - GlobeNewswire - Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress
05/27/2021 / 22:01 - GlobeNewswire - Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting
05/18/2021 / 22:01 - GlobeNewswire - Galapagos refocuses pipeline and rightsizes operations
05/06/2021 / 22:01 - GlobeNewswire - Transparency notification received from The Capital Group
05/04/2021 / 22:01 - GlobeNewswire - Scipher Applies Spectra™ Platform to Discover Drugs Targeting Autoimmune Patients Refractory to Existing Therapies
05/04/2021 / 14:00 - GlobeNewswire - CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
05/04/2021 / 11:00 - GlobeNewswire - Galapagos creates new subscription right plans
04/30/2021 / 22:01 - GlobeNewswire - Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies
04/23/2021 / 06:01 - GlobeNewswire - OXURION NV to Present at Wet AMD and DME Drug Development Summit
04/13/2021 / 07:30 - GlobeNewswire - Extension of lock-up period in Gilead-Galapagos collaboration agreement
04/08/2021 / 22:01 - GlobeNewswire - Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
04/07/2021 / 17:45 - GlobeNewswire - Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group
04/06/2021 / 07:30 - GlobeNewswire - Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger
04/05/2021 / 14:15 - GlobeNewswire
Real-time